SLC5A2 and type 2 diabetes mellitus: As weight loss is a major contributor to decreasing liver fat and ameliorating outcomes in MASLD, the data emerging from AWARD-10 study are yet another additional form evidence reinforcing benefits of GLP1 RAs combined with SGLT2 inhibitors for those individuals having T2DM accompanied by MASLD [147].